Neurocrine Biosciences Inc
NBIX
NASDAQ
Biotechnology
$152.72
USD
+1.90 (+1.26%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $15.51B
Volume 1.3M
Revenue
$3.37B
TTM
+34.4%
YoY
Gross Margin
98%
TTM
-0.6%
YoY
Net Income
$705.50M
TTM
+102.6%
YoY
Operating Cash Flow
$898.10M
TTM
+58.3%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 687.5 | 794.9 | 805.5 | 814.5 | 959.0 |
YoY Growth | +16.5% | +27.8% | +28.3% | +42.2% | +39.5% |
Cost of Revenue | 10.3 | 14.0 | 17.6 | 13.8 | 23.2 |
Gross Profit | 677.2 | 780.9 | 787.9 | 800.7 | 935.8 |
Selling, General & Administrative | 286.3 | 291.6 | 301.8 | 318.5 | 439.7 |
Other Operating Expenses | 0.0 | 0.3 | 17.0 | 21.2 | 1.5 |
Total Operating Expenses | 531.6 | 541.9 | 577.0 | 635.9 | 784.3 |
Operating Income | 145.6 | 239.0 | 210.9 | 164.8 | 151.5 |
EBITDA | 150.9 | 247.0 | 235.4 | 193.3 | 161.3 |
Other Income / Expense | -6.7 | 30.6 | 2.7 | 53.9 | 1.2 |
Total Other Income / Expense | 13.9 | 52.8 | 28.5 | 82.0 | 10.7 |
Income Before Income Taxes | 159.5 | 291.8 | 239.4 | 246.8 | 162.2 |
Income Taxes | 52.0 | 82.3 | 85.7 | 48.9 | 17.8 |
Net Income | 107.5 | 209.5 | 153.7 | 197.9 | 144.4 |
Consolidated Net Income / Loss | 107.5 | 209.5 | 153.7 | 197.9 | 144.4 |
Net Income Attributable to Common Shareholders | 107.5 | 209.5 | 153.7 | 197.9 | 144.4 |
Basic EPS | $1.09 | $2.11 | $1.54 | $1.97 | $1.43 |
Diluted EPS | $1.06 | $2.04 | $1.48 | $1.91 | $1.39 |
Basic Shares Outstanding | 99.0M | 99.4M | 99.9M | 100.5M | 101.0M |
Diluted Shares Outstanding | 101.0M | 102.5M | 104.0M | 103.4M | 104.2M |